EMERGENT BIOSOLUTIONS INC. Cost of Revenue
EMERGENT BIOSOLUTIONS INC. (EBS) reported Cost of Revenue of $97.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. cost of goods and services sold for the quarter ending 2026-06-30 was $97.10M, a 45.14% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. cost of goods and services sold for the quarter ending 2026-03-31 was $72.00M, a 18.64% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. cost of goods and services sold for the quarter ending 2025-12-31 was $84.90M, a 28.05% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. cost of goods and services sold for the quarter ending 2025-09-30 was $85.90M, a 29.93% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. cost of goods and services sold for fiscal 2025 was $326.20M, a 52.12% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. cost of goods and services sold for fiscal 2024 was $681.30M, a 3.42% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. cost of goods and services sold for fiscal 2023 was $705.40M, a 1.77% increase from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. cost of goods and services sold for fiscal 2022 was $693.10M, a 7.35% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $97.10M 10-Q · filed 2026-08-06 | $169.10M 10-Q · filed 2026-08-06 | $254.00M derived: sum of 3 quarters · filed 2026-08-06 | $339.90M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $72.00M 10-Q · filed 2026-05-01 | $156.90M derived: sum of 2 quarters · filed 2026-05-01 | $242.80M derived: sum of 3 quarters · filed 2026-05-01 | $309.70M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $84.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $170.80M derived: sum of 2 quarters · filed 2026-02-27 | $237.70M derived: sum of 3 quarters · filed 2026-08-06 | $326.20M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $85.90M 10-Q · filed 2025-10-30 | $152.80M derived: sum of 2 quarters · filed 2026-08-06 | $241.30M 10-Q · filed 2025-10-30 | $359.30M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $66.90M 10-Q · filed 2026-08-06 | $155.40M 10-Q · filed 2026-08-06 | $273.40M derived: sum of 3 quarters · filed 2026-08-06 | $396.00M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $88.50M 10-Q · filed 2026-05-01 | $206.50M derived: sum of 2 quarters · filed 2026-05-01 | $329.10M derived: sum of 3 quarters · filed 2026-05-01 | $625.20M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | $118.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $240.60M derived: sum of 2 quarters · filed 2026-02-27 | $536.70M derived: sum of 3 quarters · filed 2026-02-27 | $681.30M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $122.60M 10-Q · filed 2025-10-30 | $418.70M derived: sum of 2 quarters · filed 2025-10-30 | $563.30M 10-Q · filed 2025-10-30 | $748.40M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | $296.10M 10-Q · filed 2025-08-07 | $440.70M 10-Q · filed 2025-08-07 | $625.80M derived: sum of 3 quarters · filed 2026-02-27 | $802.60M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $144.60M 10-Q · filed 2025-05-08 | $329.70M derived: sum of 2 quarters · filed 2026-02-27 | $506.50M derived: sum of 3 quarters · filed 2026-02-27 | $697.10M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | $185.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $361.90M derived: sum of 2 quarters · filed 2026-02-27 | $552.50M derived: sum of 3 quarters · filed 2026-02-27 | $705.40M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $176.80M 10-Q · filed 2024-11-07 | $367.40M derived: sum of 2 quarters · filed 2024-11-07 | $520.30M 10-Q · filed 2024-11-07 | $740.80M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $190.60M 10-Q · filed 2024-08-07 | $343.50M 10-Q · filed 2024-08-07 | $345.70M 10-Q · filed 2023-08-09 | $564.00M derived: sum of 3 quarters · filed 2024-08-07 | $711.20M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-03-31 | $152.90M 10-Q · filed 2024-05-02 | $155.10M 10-Q · filed 2023-05-10 | $373.40M derived: sum of 2 quarters · filed 2024-05-02 | $520.60M derived: sum of 3 quarters · filed 2024-05-02 | $690.40M derived: sum of 4 quarters · filed 2024-05-02 | |||
| 2022-12-31 | $220.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $367.70M derived: sum of 2 quarters · filed 2024-03-08 | $537.50M derived: sum of 3 quarters · filed 2024-03-08 | $693.10M 10-K · filed 2024-03-08 | $693.70M 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $147.20M 10-Q · filed 2023-12-11 | $317.00M derived: sum of 2 quarters · filed 2023-12-11 | $472.60M 10-Q · filed 2023-12-11 | |||||
| 2022-06-30 | $169.80M 10-Q · filed 2023-08-09 | $325.70M 10-Q · filed 2023-08-09 | ||||||
| 2022-03-31 | $155.90M 10-Q · filed 2023-05-10 | |||||||
| 2021-12-31 | $748.10M 10-K · filed 2024-03-08 | $757.50M 10-K · filed 2023-03-01 | ||||||
| 2021-06-30 | $227.80M 10-Q · filed 2021-07-30 | $327.10M 10-Q · filed 2021-07-30 | $508.40M derived: sum of 3 quarters · filed 2023-12-11 | $657.40M derived: sum of 4 quarters · filed 2023-12-11 | ||||
| 2021-03-31 | $99.30M 10-Q · filed 2021-04-30 | $280.60M derived: sum of 2 quarters · filed 2023-12-11 | $429.60M derived: sum of 3 quarters · filed 2023-12-11 | $559.40M derived: sum of 4 quarters · filed 2023-12-11 | ||||
| 2020-12-31 | $181.30M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $330.30M derived: sum of 2 quarters · filed 2023-12-11 | $460.10M derived: sum of 3 quarters · filed 2023-12-11 | $537.00M 10-K/A · filed 2023-12-11 | $524.00M 10-K · filed 2021-02-19 | |||
| 2020-09-30 | $149.00M 10-Q · filed 2020-11-06 | $278.80M derived: sum of 2 quarters · filed 2021-07-30 | $355.70M 10-Q · filed 2020-11-06 | $488.50M derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2020-06-30 | $129.80M 10-Q · filed 2021-07-30 | $206.70M 10-Q · filed 2021-07-30 | $339.50M derived: sum of 3 quarters · filed 2021-07-30 | $447.50M derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2020-03-31 | $76.90M 10-Q · filed 2021-04-30 | $209.70M derived: sum of 2 quarters · filed 2021-04-30 | $317.70M derived: sum of 3 quarters · filed 2021-04-30 | $418.50M derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-31 | $132.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $240.80M derived: sum of 2 quarters · filed 2021-02-19 | $341.60M derived: sum of 3 quarters · filed 2021-02-19 | $433.50M 10-K · filed 2021-02-19 | ||||
| 2019-09-30 | $108.00M 10-Q · filed 2020-11-06 | $208.80M derived: sum of 2 quarters · filed 2020-11-06 | $300.70M 10-Q · filed 2020-11-06 | $414.10M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-06-30 | $100.80M 10-Q · filed 2020-07-31 | $192.70M 10-Q · filed 2020-07-31 | $306.10M derived: sum of 3 quarters · filed 2021-02-19 | $375.40M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-03-31 | $91.80M 10-Q · filed 2020-05-01 | $205.30M derived: sum of 2 quarters · filed 2021-02-19 | $274.60M derived: sum of 3 quarters · filed 2021-02-19 | $359.90M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2018-12-31 | $113.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $182.80M derived: sum of 2 quarters · filed 2021-02-19 | $268.10M derived: sum of 3 quarters · filed 2021-02-19 | $322.30M 10-K · filed 2021-02-19 | ||||
| 2018-09-30 | $69.30M 10-Q · filed 2019-11-07 | $73.23M 10-Q · filed 2018-11-02 | $154.60M derived: sum of 2 quarters · filed 2019-11-07 | $208.80M 10-Q · filed 2019-11-07 | $220.45M 10-Q · filed 2018-11-02 | $271.15M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | $85.30M 10-Q · filed 2019-08-02 | $89.17M 10-Q · filed 2018-08-03 | $139.40M 10-Q · filed 2019-08-02 | $147.22M 10-Q · filed 2018-08-03 | $201.85M derived: sum of 3 quarters · filed 2020-02-25 | $246.35M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | $54.30M 10-Q · filed 2019-05-08 | $116.55M derived: sum of 2 quarters · filed 2020-02-25 | $161.05M derived: sum of 3 quarters · filed 2020-02-25 | $195.68M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2017-12-31 | $62.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $106.75M derived: sum of 2 quarters · filed 2020-02-25 | $141.38M derived: sum of 3 quarters · filed 2020-02-25 | $187.70M 10-K · filed 2020-02-25 | ||||
| 2017-09-30 | $44.50M 10-Q · filed 2018-11-02 | $79.13M derived: sum of 2 quarters · filed 2018-11-02 | $125.45M 10-Q · filed 2018-11-02 | |||||
| 2017-06-30 | $34.62M 10-Q · filed 2018-08-03 | $80.95M 10-Q · filed 2018-08-03 | ||||||
| 2016-12-31 | $126.30M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |